NEUROCRINE BIOSCIENCES INC Current Liabilities
NEUROCRINE BIOSCIENCES INC (NBIX) had Current Liabilities of $874.50 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-07-31
- 2026-06-30: Liabilities, Current $874.50M.
- 2026-03-31: Liabilities, Current $831.70M.
- 2025-12-31: Liabilities, Current $743.40M.
- 2025-09-30: Liabilities, Current $638.00M.
| Period end | Liabilities, Current | Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $874.50M 10-Q · filed 2026-07-31 | |
| 2026-03-31 | $831.70M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $743.40M 10-Q · filed 2026-07-31 | |
| 2025-09-30 | $638.00M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $546.30M 10-Q · filed 2025-07-30 | |
| 2025-03-31 | $522.90M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $507.70M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $429.70M 10-Q · filed 2024-10-30 | |
| 2024-06-30 | $398.50M 10-Q · filed 2024-08-01 | |
| 2024-03-31 | $712.90M 10-Q · filed 2024-05-01 | |
| 2023-12-31 | $654.80M 10-K · filed 2025-02-10 | |
| 2023-09-30 | $691.60M 10-Q · filed 2023-10-31 | |
| 2023-06-30 | $582.50M 10-Q · filed 2023-08-01 | |
| 2023-03-31 | $374.10M 10-Q · filed 2023-05-03 | |
| 2022-12-31 | $537.70M 10-K · filed 2024-02-09 | |
| 2022-09-30 | $485.10M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $285.70M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $253.50M 10-Q · filed 2022-05-04 | |
| 2021-12-31 | $245.80M 10-K · filed 2023-02-09 | |
| 2021-09-30 | $225.90M 10-Q · filed 2021-11-01 | |
| 2021-06-30 | $212.90M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $190.00M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $186.50M 10-K · filed 2022-02-11 | |
| 2020-09-30 | $611.00M 10-Q · filed 2020-11-09 | |
| 2020-06-30 | $573.00M 10-Q · filed 2020-08-03 | |
| 2020-03-31 | $140.30M 10-Q · filed 2020-05-06 | |
| 2019-12-31 | $565.30M 10-K · filed 2021-02-05 | $565.29M 10-K · filed 2020-02-07 |
| 2019-09-30 | $115.65M 10-Q · filed 2019-11-04 | |
| 2019-06-30 | $100.59M 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $72.00M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $88.23M 10-K · filed 2020-02-07 | |
| 2018-09-30 | $456.40M 10-Q · filed 2018-11-05 | |
| 2018-06-30 | $61.76M 10-Q · filed 2018-07-31 | |
| 2018-03-31 | $46.47M 10-Q · filed 2018-04-30 | |
| 2017-12-31 | $54.43M 10-K · filed 2019-02-08 | |
| 2017-09-30 | $38.14M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $27.72M 10-Q · filed 2017-08-03 | |
| 2017-03-31 | $23.56M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $30.41M 10-K · filed 2018-02-13 | |
| 2016-09-30 | $26.67M 10-Q · filed 2016-11-02 | |
| 2016-06-30 | $26.90M 10-Q · filed 2016-08-03 | |
| 2016-03-31 | $23.28M 10-Q · filed 2016-05-05 | |
| 2015-12-31 | $25.71M 10-K · filed 2017-02-14 | |
| 2015-09-30 | $19.82M 10-Q · filed 2015-10-29 | |
| 2015-06-30 | $17.55M 10-Q · filed 2015-07-29 | |
| 2015-03-31 | $15.19M 10-Q · filed 2015-04-30 | |
| 2014-12-31 | $15.66M 10-K · filed 2016-02-11 | |
| 2014-09-30 | $14.04M 10-Q · filed 2014-11-04 | |
| 2014-06-30 | $12.05M 10-Q · filed 2014-08-06 | |
| 2014-03-31 | $10.61M 10-Q · filed 2014-05-01 | |
| 2013-12-31 | $11.70M 10-K · filed 2015-02-09 | |
| 2013-09-30 | $13.32M 10-Q · filed 2013-10-29 | |
| 2013-06-30 | $14.57M 10-Q · filed 2013-07-26 | |
| 2013-03-31 | $13.88M 10-Q · filed 2013-05-02 | |
| 2012-12-31 | $15.65M 10-K · filed 2014-02-11 | |
| 2012-09-30 | $23.11M 10-Q · filed 2012-10-31 | |
| 2012-06-30 | $29.15M 10-Q · filed 2012-07-31 | |
| 2012-03-31 | $36.63M 10-Q · filed 2012-05-02 | |
| 2011-12-31 | $47.11M 10-K · filed 2013-02-08 | |
| 2011-09-30 | $48.44M 10-Q · filed 2011-10-31 | |
| 2011-06-30 | $49.99M 10-Q · filed 2011-07-29 | |
| 2010-12-31 | $52.78M 10-K · filed 2012-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |